These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25937541)

  • 21. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes.
    Huang Y; Sun J; Wang X; Tao X; Wang H; Tan W
    J Clin Pharm Ther; 2015 Aug; 40(4):461-5. PubMed ID: 26032654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is the phenotype of patients with gastrointestinal intolerance to metformin?
    Hermans MP; Ahn SA; Rousseau MF
    Diabetes Metab; 2013 Sep; 39(4):322-9. PubMed ID: 23786968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
    Mathieu C; Rodbard HW; Cariou B; Handelsman Y; Philis-Tsimikas A; Ocampo Francisco AM; Rana A; Zinman B;
    Diabetes Obes Metab; 2014 Jul; 16(7):636-44. PubMed ID: 24443830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.
    Kajiwara M; Tanaka A; Kawasaki T; Nakao K; Sakamoto T; Toyoda S; Inoue T; Koga N; Node K
    J Cardiol; 2017 Mar; 69(3):511-517. PubMed ID: 27894787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
    Kumarathurai P; Anholm C; Fabricius-Bjerre A; Nielsen OW; Kristiansen O; Madsbad S; Haugaard SB; Sajadieh A
    J Hypertens; 2017 May; 35(5):1070-1078. PubMed ID: 28129251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice.
    Sauer N; Reining F; Schulze Zur Wiesch C; Burkhardt T; Aberle J
    Horm Metab Res; 2015 Jul; 47(8):560-4. PubMed ID: 25230325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.
    Díaz-Soto G; de Luis DA; Conde-Vicente R; Izaola-Jauregui O; Ramos C; Romero E
    Diabetes Res Clin Pract; 2014 Apr; 104(1):92-6. PubMed ID: 24530118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.
    Liou JH; Liu YM; Chen CH
    Transplant Proc; 2018 Oct; 50(8):2502-2505. PubMed ID: 30316386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.
    Mather KJ; Considine RV; Hamilton L; Patel NA; Mathias C; Territo W; Goodwill AG; Tune JD; Green MA; Hutchins GD
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3456-3465. PubMed ID: 30020461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain.
    Gomez-Peralta F; Lecube A; Fernández-Mariño A; Alonso Troncoso I; Morales C; Morales-Pérez FM; Guler I; Cadarso-Suárez C
    Diabet Med; 2018 Nov; 35(11):1605-1612. PubMed ID: 29943854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of complex treatment influence on systemic inflammation in overweight type 2 diabetes patients.
    Said OV; Velychko VI; Danylchuk HO
    Wiad Lek; 2018; 71(6):1141-1146. PubMed ID: 30267490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved.
    Trenson L; Trenson S; van Nes F; Moyson C; Lannoo M; Deleus E; Meulemans A; Matthys C; Mertens A; Van der Schueren B; Vangoitsenhoven R
    Obes Facts; 2022; 15(1):83-89. PubMed ID: 34808630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.
    Bruinstroop E; Meyer L; Brouwer CB; van Rooijen DE; van Dam PS
    Diabetes Ther; 2018 Jun; 9(3):1369-1375. PubMed ID: 29779196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
    Ebell MH
    Am Fam Physician; 2023 Apr; 107(4):434. PubMed ID: 37054429
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide.
    Long J; Liu Y; Duan Y; Li Y; Yang G; Ren Z; Tao W; Liu D
    Eur J Clin Pharmacol; 2022 Apr; 78(4):589-596. PubMed ID: 35034150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by
    Dawed AY; Zhou K; van Leeuwen N; Mahajan A; Robertson N; Koivula R; Elders PJM; Rauh SP; Jones AG; Holl RW; Stingl JC; Franks PW; McCarthy MI; 't Hart LM; Pearson ER;
    Diabetes Care; 2019 Jun; 42(6):1027-1033. PubMed ID: 30885951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.